TrialEBioMedicine2020

Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).

Rosa De Miguel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.